Neoadjuvant chemoimmunotherapy superior to neoadjuvant chemotherapy with event-free survival benefit in patients with resectable NSCLC and tumour PD-L1 less than 1%

 A recently published meta-analysis, conducted within the Department of Surgery at McGill University, concluded that "neoadjuvant chemoimmunotherapy as associated with improved overall survival, event-free survival, major pathological response and pathological complete response" compared to neoadjuvant chemotherapy alone in non-small cell lung cancer (NSCLC) patients.  In particular, improvements were noted in patients diagnosed with either stage II or stage III NSCLC.   

To learn more about this study, click here. 

Sources mentioned: 

• Sorin M, Prosty C, Ghaleb L, et al. Neoadjuvant Chemoimmunotherapy for NSCLC A Systematic Review and Meta-Analysis. JAMA Oncology; Published online 21 March 2024. doi:10.1001/jamaoncol.2024.0057
• Rolfo C, Russo A. The Chemoimmunotherapy Revolution in Resectable NSCLC—The Times They Are A-Changin’. JAMA Oncology; Published online 21 March 2024. doi:10.1001/jamaoncol.2024.0043